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Abstract
Introduction: The purpose of this study was to investigate the profile of histone deacetylase (HDAC) expression in the 
synovial tissue of rheumatoid arthritis (RA) compared with that of normal control and osteoarthritis (OA), and to 
examine whether there is a link between HDAC activity and synovial inflammation.
Methods: HDAC activity and histone acetyltransferase (HAT) activity were determined in nuclear extracts of total 
synovial tissue surgically obtained from normal, OA and RA joints. The level of cytoplasmic tumor necrosis factor a 
(TNFα) fraction was measured by ELISA. Total RNA of synovial tissue was used for RT-PCR of HDAC1-8. In synovial 
fibroblasts from RA (RASFs), the effects of TNFα on nuclear HDAC activity and class I HDACs (1, 2, 3, 8) mRNA 
expressions were examined by quantitative real-time PCR. The protein expression and distribution of class I HDACs 
were examined by Western blotting.
Results: Nuclear HDAC activity was significantly higher in RA than in OA and normal controls and correlated with the 
amount of cytoplasmic TNFα. The mRNA expression of HDAC1 in RA synovial tissue was higher than in OA and normal 
controls, and showed positive correlation with TNFα mRNA expression. The protein level of nuclear HDAC1 was higher 
in RA synovial tissue compared with OA synovial tissue. Stimulation with TNFα significantly increased the nuclear HDAC 
activity and HDAC1 mRNA expression at 24 hours and HDAC1 protein expression at 48 hours in RASFs.
Conclusions: Our results showed nuclear HDAC activity and expression of HDAC1 were significantly higher in RA than 
in OA synovial tissues, and they were upregulated by TNFα stimulation in RASFs. These data might provide important 
clues for the development of specific small molecule HDAC inhibitors.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic inflammation of the synovial
tissues in multiple joints that leads to bone and joint
destruction. Recent clinical application of biologic agents
targeted to inflammatory cytokines including tumor
necrosis factor α (TNFα) or interleukin-1β (IL)-1β dra-
matically changed the treatment strategy for RA. These
molecular therapies of RA are more effective than the
conventional disease-modifying anti-rheumatic drugs
(DMARDs), and can even stop the destructive process in
some RA patients [1]. Nevertheless, the etiology of RA
inflammation still remains unknown, and there is a
demand for developing new therapies with alternative
targets.
The characteristic pathology of the RA synovial mem-
brane, including synovial cell proliferation, and persistent
recruitment, activation, retention and survival of infil-
trated immune cells, might require epigenetic regulation
of gene transcription, such as acetylation, methylation
and ubiquitination [2]. Among these, histone modifica-
tion through reversible acetylation is a crucial event in
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gene expression [3]. Histone acetylation is controlled by
two enzymes, histone acetyltransferase (HAT) and his-
tone deacetylase (HDAC) [4,5]. Mammalian HDACs are
classified into two major classes [6]. Class I HDACs
(HDACs 1, 2, 3, 8) are homologues of yeast PRD3 and are
found exclusively in the nucleus. Class II HDACs
(HDACs 4 to 7 and 9), homologues of yeast Hda1, are
found in both the nucleus and the cytoplasm. Gene regu-
lation by HDAC/HAT is complex, because the inhibition
of HDAC activity results both in induction and repres-
sion of gene expression, depending on the cell types and
cell lines [7-11]. Recent studies on the balance of HAT
and HDAC activity in human RA synovial tissue indi-
cated that HDAC activity was significantly decreased in
RA synovial tissue compared to osteoarthritis (OA) and
n o r m a l  t i s s u e s ,  t h u s  H D A C / H A T  m i g h t  b e  s t r o n g l y
shifted toward histone hyperacetylation in RA patients
[12].
Inhibitors of HDACs, originally developed as anti-can-
cer agents, exhibit anti-proliferative activity of the cells
through multiple mechanisms, such as induction of apop-
tosis, cell cycle arrest, and promotion of cell differentia-
tion, via modulation of gene expression [13]. It was
r e p o r t e d  t h a t  H D A C  i n h i b i t o r s  c a n  a l s o  r e d u c e  t h e
expression of inflammatory mediators, such as TNFα, IL-
1β, IL-6, IL-8, transforming growth factor-β, and nitric
oxide that are involved in the pathogenesis of inflamma-
tory diseases [13-18]. We have reported recently that
FK228, an inhibitor of class I HDAC shows inhibitory
effects on the proliferation of synovial fibroblasts from
RA (RASFs) and ameliorates collagen antibody-induced
pathology in mice [19]. The inhibition of cell proliferation
by FK228 treatment was accompanied by the induction of
p16INK4a and the up-regulation of p21WAF1/Cip1 expression
in RASFs. Moreover, the expression of TNFα and IL-1β
was markedly reduced in the synovium of mice treated by
FK228. However, it remains unknown which HDACs are
specifically involved in the process of RA inflammation.
This information would be necessary for the develop-
ment of new drugs that would avoid adverse side-effects
including haematological toxicity and gastrointestinal
symptoms [20,21]. It is unclear why the inhibition of
HDAC ameliorates experimentally-induced arthritis
[19,22] if HDAC/HAT is shifted toward histone hyper-
acetylation [12].
Here we investigated the expression profiles of class I
and II HDACs (HDAC 1-8) in OA and RA synovial tis-
sues, to identify the candidate HDAC gene in synovial
inflammation in RA. We examined HAT and HDAC
activities in the total nuclear extracts of synovial tissues
from RA patients predominantly treated with conven-
tional DMARDs, and their relationship with the cytoplas-
mic level of TNFα. Our data might provide new leads
toward future developments of specific HDAC inhibitors
for epigenetic regulation of RA.
Materials and methods
Patients and tissue sampling
We obtained total synovial tissue specimens from 15 RA
and 13 OA patients, and 3 normal control patients under-
going orthopedic surgery at Okayama University Hospi-
tal, with informed consent from the patients. All RA
patients fulfilled the 1987 revised criteria of the Ameri-
can Rheumatism Association [23]. The study protocol is
approved by Okayama University Institutional Review
Board (accredited ISO9001/2000) and by local ethic com-
mittees at respective institute where available. Normal
synovial tissues were obtained from amputation surgery
for a malignant tumor (n = 1), and ligament reconstruc-
tion surgery (n = 2). Baseline characteristics of the
patients are summarized in Table 1. Most RA patients
were receiving nonsteroidal anti-inflammatory drugs
Table 1: Characteristics of the study subjects
Normal OA RA
Age mean (yr) 19.3 ± 5.0 75.9 ± 1.0 65.4 ± 2.2
No. of patients 3 13 15
Sex (F/M) 0/3 13/0 14/1
Disease duration (yr) N/A 8.6 ± 2.2 15.9 ± 2.7
CRP (mg/dl) 0.2 ± 0.1 0.1 ± 0.4 1.4 ± 0.4
Medication (no of patients)
Oral corticosteroid (mg/dl) 0 0 11(4.3 ± 0.5)
Methotrexate (mg/day) 0 0 9 (6.8 ± 0.8)
DMARDs others 0 0 6
NSAIDs 0 5 9
OA, osteoarthritis; RA, rheumatoid arthritis; NA, not applicable; Values are means ± SE.Kawabata et al. Arthritis Research & Therapy 2010, 12:R133
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(NSAIDs), oral corticosteroid at ≤7.5 mg, and DMARDs
such as methotrexate (MTX) and sulfasalazine, but not
anti-TNFα treatment. RA patients had active disease, as
indicated by increased acute-phase reactants (serum C-
reactive protein (CRP) level 14.3 ± 4.1 mg/liter). OA
patients and normal controls exhibited no evidence of
inflammatory response. Fresh synovial tissues were
divided immediately into approximate portions of 333 mg
for measurement of HDAC activity, and 30 mg for real-
time RT-PCR analysis and stored at -80°C.
Isolation and culture of human RASFs
Fresh synovial tissues were obtained, with written per-
mission from three RA patients during total joint replace-
ment surgery. The tissues were minced and then
immediately digested with 0.2% collagenase (Wako,
Osaka, Japan) and DNAase (Sigma-Aldrich St. Louis,
MO, USA) at 37°C, as previously described [24]. Tissue
debris was removed with a cell strainer, and the remain-
ing cells were washed twice with medium consisting of
Dulbecco's modified Eagle's medium (DMEM; Sigma-
Aldrich) supplemented with 10% HEPES (Life Technolo-
gies, Tokyo, Japan), 100 IU penicillin/ml, and 100 mg of
streptomycin/ml (Life Technologies). The resultant single
cells were dispensed into the wells of a 24-well microtiter
plate (Costar, Cambridge, MA, USA) at a density of 2 ×
106 cells/ml in 2 ml of DMEM supplemented with 10%
fetal bovine serum (FBS), 100 IU of penicillin/ml, and 100
mg of streptomycin/ml. The plates were incubated at
37°C in a humidified atmosphere containing 5% CO2.
Synovial cell cultures were divided once weekly until the
primary cultures had reached confluence. After the third
passage, morphologically homogeneous fibroblast-like
cells were obtained. These synovial fibroblast cell lines
(Passage 4 to 7) were incubated at a density of 1 × 105
cells/ml in 10% FBS/DMEM and after 24 h, in 1% FBS/
DMEM overnight.
Preparation of nuclear and cytoplasmic extracts
Nuclear and cytoplasmic extracts were obtained from
total synovial tissue specimens (333 mg) of patients and
cultured RASFs (3.2 × 106  cells), using the Nuclear
Extract kit (Active Motif, Carlsbad, CA, USA) according
to the manufacturer's instructions. RASFs were incu-
bated with or without 10 ng/ml of recombinant TNFα (R
& D Systems, Minneapolis, MN, USA) at the indicated
time (0, 3, 6, 12, 24 h) and (0, 24, 48 h) before extraction.
Supernatants were harvested as cytoplasmic fractions.
Pellets were resuspended in 100 μl (synovial tissue) and
25 μl (RASFs) of Complete Lysis Buffer and centrifuged at
14,000 × g for 10 minutes at 4°C; supernatants were saved
as the nuclear fractions. The protein concentration of
each sample was measured (Bradford Bio-Rad Protein
Assay kit, Bio Rad, San Diego, CA, USA), with bovine
serum albumin used as a standard.
Measurement of HDAC activity
HDAC activity was measured with a non-isotopic assay
that used a fluorescent derivative of epsilon-acetyl lysine
(HDAC Fluorescent Activity Assay Kit, Biomol, Plym-
outh Meeting, PA, USA), according to the manufacturer's
instructions. Briefly, 6 μg nuclear protein was diluted in
assay buffer and incubated at 37°C with cell extracts and
trichostatin A (TSA), a classic HDAC inhibitor, and then
the HDAC reaction was initiated by the addition of Fluor-
de-Lys substrate. After 10 minutes, Fluor-de-Lys Devel-
oper was added, and the mixture was incubated for
another 10 minutes at room temperature. Fluorescence
was measured using a microplate reader (DS Pharma Bio-
medical, Suita, Osaka, Japan) with excitation at 380 nm
and emission at 460 nm. The HDAC activity was
expressed as arbitrary fluorescence units. The results are
expressed as micromolar values of the provided standard
per 6 μg of protein.
Measurement of HAT activity
HAT activity was measured using a commercially avail-
able, non-radioactive HAT activity assay kit (Active
Motif, Co., Ltd, Carlsbad, CA, USA), according to the
detailed instructions provided by the manufacturer.
Nuclear extracts were prepared from synovial tissues
obtained from five OA and five RA patients. Briefly, 3 μg
nuclear protein was incubated in HAT assay buffer con-
taining 0.5 mM acetyl-CoA and histone H3 peptide (5.16
μg) for 30 minutes at room temperature. The reaction
was stopped by adding the stop solution, and after adding
the complete developing solution the mixture was incu-
bated for another 15 minutes at room temperature. Fluo-
rescence was measured using a microplate reader (DS
Pharma Biomedical) with excitation at 380 nm and emis-
sion at 460 nm. The HAT activity was expressed as arbi-
trary fluorescence units. The results are expressed as
micromolar values of the provided standard per 3 μg of
protein.
Immunoassays for TNFα
TNFα plays a central role in regulating pro-inflammatory
and anti-inflammatory cytokines in normal, OA and RA
synovial tissue. The concentration of TNFα in the cyto-
plasmic fraction of total synovial tissue was measured by
the quantitative sandwich enzyme-linked immunosor-
bent assay (ELISA) using cytokine-specific capture and
biotinylated detection mAbs and recombinant cytokine
proteins (all from BD Biosciences, San Jose, CA, USA)
according to the manufacturer's protocol. The detection
limit of the kit for TNFα was 7.8 pg/ml.Kawabata et al. Arthritis Research & Therapy 2010, 12:R133
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Quantitative real-time RT-PCR for HDAC1-8 and TNFα
Total RNA was extracted from total synovial tissue 30 mg
in size with the use of an RNeasy Fibrous Tissue Mini Kit
(Quiagen, Valencia, CA, USA) and was extracted from
RASFs (n = 3) after stimulation by recombinant TNFα (10
ng/ml) at the indicated time (0, 3, 6, 24 h) using TRIzol
according to the instructions of the manufacturer (Invit-
rogen, Carlsbad, CA, USA). Two micrograms of total
RNA was reverse transcribed to complementary DNA
(cDNA) with random primers according to the manufac-
turer's protocol (Toyobo, Osaka, Japan).
Quantitative real-time RT-PCR analysis was performed
using a LightCycler Rapid Thermal Cycling system
(Roche Diagnostics, Indianapolis, IN, USA), according to
a previously reported protocol [25-27]. The PCR mixture
consisted of 1 × SYBR Green PCR Master Mix, which
includes DNA polymerase, SYBR Green I dye, dNTPs
(including dUTP), PCR buffer, 10 pmoles of forward and
reverse primers, and cDNA of samples, in a total volume
of 20 μl. Amplification of a housekeeping gene, β-actin,
was used for normalizing the efficiency of cDNA synthe-
sis and the amount of RNA applied. The sequences of the
oligonucleotide primers (HDAC1-8) used are shown in
Table 2 and TNFα primer (Roche Diagnostics) was used.
Western blotting for class I HDACs
Nuclear extracts (20 μg of total protein/lane from syn-
ovial tissue and 5 μg of total protein/lane from RASF)
were subjected to SDS-PAGE using a 5 to 12% gradient
gel, and then transferred onto nitrocellulose membranes
(Advantech Co., Ltd, Tokyo, Japan). The membranes were
blocked with 5% skim milk and 0.05% Tween 20 in TBS
(pH 7.4) for 1 h. and were then incubated with primary
antibody in 0.05% Tween 20 in TBS (pH 7.4) overnight at
4°C with polyclonal antibodies against HDAC1, 2, 3, 8
(Santa Cruz Biotechnology, Santa Cruz, CA, USA,
HDAC1:SC-7872, HDAC2:SC-7899, HDAC3:SC-11417,
HDAC8:SC-11405) and lamin A (Abcam Ltd., Cam-
bridge, UK, ab8980). After washing, blots were stained
with appropriate horseradish peroxidase-conjugated sec-
ondary antibody. Immunoreactive bands were detected
by enhanced chemiluminescence (ECL plus solution,
Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Protein expression level was quantitated by densitometric
analysis as previously reported [28]. Briefly, the intensity
of the bands were measured by Image J software,
Bethesda, MD, USA [29] and lamin A, a nuclear protein,
was used for loading controls.
Statistical analysis
All results are expressed as means ± SE. Statistical signifi-
cance of differences between two groups was determined
by the Mann-Whitney U test. Other analysis was per-
formed to compare differences among groups by one-way
analysis of variance followed by the Bonnferoni correc-
tion. A P-value of less than 0.05 was considered statisti-
cally significant.
Results
Measurement of HDAC activity in RA, OA and normal 
synovial tissues
Total nuclear HDAC activity (expressed as micromolar
values of the deacetylated HDAC substrate standard per 6
μg of protein) in samples of synovial tissue from RA
patients (n = 14) was 0.96 ± 0.08 μM of the HDAC stan-
dard. This level of activity was significantly higher than
those from OA (n = 12, HDAC activity; 0.62 ± 0.09, P =
0.0052) and from normal controls (n = 3, HDAC activity;
0.50 ± 0.04, P = 0.015) (Figure 1a).
Measurement of HAT activity in RA, OA and normal synovial 
tissues
Total nuclear HAT activity was measured in synovial tis-
sues from normal controls (7.04 ± 1.78 μM, n = 3), from
OA (7.23 ± 1.35 μM, n = 5) and from RA (6.28 ± 1.06 μM,
n = 5) (Figure 1b). There was no significant difference
between normal controls, OA and RA synovial tissues
( F igur e 1b ).  W e  e xa m ined t he  r a t io o f  HD A C  t o HA T
activity on the same patients (OA: n = 5, RA: n = 5), but
failed to show the significant difference in the ratio of
HDAC to HAT activity between OA and RA groups. This
might be partly due to small data set, but, at least, HDAC/
HAT was not shifted toward histone hyperacetylation.
Table 2: Primer pairs for PCR detection
HDAC1 F AGACAGCTGTGGCCCTGGATAC
R CGGCAGCATTCTAAGGTTCTCAA
HDAC2 F TGCAGTTGCCCTTGATTGTGA
R ATCTGGACACCAGGTGCATGAG
HDAC3 F AGAGTGGCCGCTACTACTGTCTGAA
R TGGGTTGGTAGAAGTCCACTACCTG
HDAC4 F GAGCAGGAGCTGGAGAAG
R AATGCAGTGGTTCAGATTCC
HDAC5 F GTGTCTCGGCTCTGCTCAGTGTAG
R TTTGCTGCAAGACTGCCTCATC
HDAC6 F GTCTACTGTGGTCGTTACATC
R GGCCTGACAGTAGTAACAC
HDAC7 F CGGGTGCACAGTAAATAC
R CCAGAGCCTTAGAGATTCATA
HDAC8 F TGACGGAATGTGCAAAGTAGCAA
R TCAAATTTCCGTCGCAATCGTA
β-actin F TTCCTGGGCATGGAGTCCT
R AGGAGGAGCAATGATCTTGATCKawabata et al. Arthritis Research & Therapy 2010, 12:R133
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Relationship between nuclear HDAC activity and 
cytoplasmic TNFα levels
To establish the relationship between nuclear HDAC
activity and cytoplasmic TNFα levels directly, we mea-
sured TNFα of the cytoplasmic fraction which was
obtained by preparing nuclear extracts of OA (n = 12)
and RA synovial tissues (n = 12). The amount of cytoplas-
mic TNFα tended to correlate with nuclear HDAC activ-
ity (OA: correlation coefficient r = 0.609, P = 0.0358, RA:
r = 0.517, P = 0.0852) (Figure 2).
Class I, class II HDACs and TNFα mRNA expressions in total 
synovial tissue
To investigate the expression profiles of class I and class II
HDACs in RA (n = 9), OA (n = 8) and normal controls (n
= 3) synovial tissues, mRNA levels of HDAC1 to 8 were
evaluated by quantitative real-time PCR. RA synovial tis-
sues expressed high levels of HDAC1 compared to OA (P
= 0.018), and normal controls (Figure 3a). HDAC4 mRNA
levels were significantly higher in normal controls than in
RA (P = 0.016). TNFα mRNA expression was measured
in RA synovial tissue. The data showed significant posi-
tive correlation between TNFα and HDAC1 mRNA in
RA synovial tissue (n = 10) (correlation coefficient r =
0.757, P = 0.012) (Figure 3b).
Nuclear expression of class I HDACs in synovial tissue
We performed Western blotting for nuclear class I
HDACs in synovial tissue. The level of nuclear HDAC1
protein expression was higher in RA synovial tissue com-
pared with OA synovial tissue (Figure 4a). Western blots
were quantified by Image J software [29]. The level of
expression of HDAC1 by normalizing to the band density
of nuclear membrane protein lamin A was significantly
higher in RA than OA synovial tissue (P = 0.0495) (Figure
4b) (see Additional file 1).
Measurement of HDAC activity, class I HDACs mRNA 
expressions and nuclear expressions in RASFs after 
treatment with TNFα
Treatment by TNFα significantly increased nuclear
HDAC activity in RASFs (n = 3) and peaked at 6 h (P =
0.0001 vs 0 and 24 h) (Figure 5a), indicating that TNFα
stimulation seems to be associated with nuclear HDAC
activity in RASFs. Next, the change of mRNA expression
in the class I HDACs after TNFα stimulation was ana-
lyzed. The expression of HDAC1 in RASFs (n = 3) was
increased after TNFα treatment; while the expressions of
other class I HDACs were not elevated through the time
course (0, 3, 6, 24 h) (Figure 5b). When the relative
mRNA expressions at 24 h after stimulation were com-
pared among class I HDACs, the increase of mRNA in
HDAC1 was significantly greater than that in other class I
HDACs (P = 0.02). We performed Western blotting for
nuclear class I HDACs in RASFs. Western blots were
quantified by Image J software. The nuclear HDAC1 pro-
tein expression in RASFs (n = 3) was elevated compared
to other class I HDACs (HDAC2, HDAC3, HDAC8) after
TNFα treatment though the time course (0, 24, 48 h). The
level of protein expressions by normalizing to the band
density of nuclear membrane protein lamin A at 48 h
after TNFα treatment tended to increase in HDAC1 (P =
0.0654; versus HDAC2, P = 0.049; versus HDAC3, P =
0.0354; versus HDAC8) (Figure 5c) (see Additional file 2).
Discussion
Previous reports indicated that HDAC inhibitors exhibit
anti-inflammatory properties, and might play a beneficial
role in the treatment of inflammatory diseases, such as
ulcerative colitis, lupus erythematosus and hepatic injury
[14,30-32]. In contrast, HDAC inhibitors have been
shown to enhance lung and microglial inflammation, sug-
gesting that HDAC inhibitors might modulate inflamma-
tion in a cell type-specific manner. We demonstrated
recently that FK228, a specific class I HDAC inhibitor,
prevents the in vivo proliferation of RASFs and amelio-
rates the pathological changes of autoantibody-mediated
arthritis in mice [19]. These results strongly suggested
that modulation of the transcriptional activity of specific
promoters in response to the local release or perturbation
of chromatin structure, by treatment with HDAC inhibi-
tors, could effectively prevent the synovial proliferation
and joint destruction seen in human RA. It is still not
known however, which HDAC was a candidate gene that
should be targeted in the process of human RA inflam-
mation.
In this study, we demonstrated that total nuclear HDAC
activity is increased in samples of human RA synovial tis-
sues compared to that in samples of OA and normal sub-
jects. Interestingly, our results were the opposite of that
reported by Huber et al [12,33]. The following factors
may lead to the discrepancies between the two studies.
First, they obtained the synovial samples during joint
replacement surgery of seven RA patients, six OA
patients and three control subjects. In RA, three patients
received TNFα blockade and all normal samples were
obtained via autopsies. As synovial tissue under TNFα
blockade would not represent the regular RA inflamma-
tion, and HDAC/HAT activity might change after mortal-
ity, we excluded the patients receiving TNFα blockade
treatment, and all samples were obtained at surgery. Sec-
ond, they demonstrated lower levels of HDAC1, and
HDAC2 protein in RA synovium than in OA by Western
blotting of whole cell lysates, with α-tubulin as an internal
control. Because HDAC1 and HDAC2 are localized
mainly at the cell nuclei, we compared the nuclear protein
levels of HDACs between RA and OA, with lamin A as an
internal control, and showed a significant increase of
HDAC1 protein in RA cells. This discrepancy might haveKawabata et al. Arthritis Research & Therapy 2010, 12:R133
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Figure 1 Total nuclear histone deacetylase (HDAC) and histone deacetylase (HAT) activity in synovial tissues. (a) Nuclear HDAC activity in syn-
ovial tissues that were obtained from rheumatoid arthritis (RA, n = 14) patients was significantly increased compared to that from normal controls (n 
= 3) and osteoarthritis (OA, n = 12). In the box (interquartile range, IQR) and whisker (maximum and minimum) plots, the horizontal line inside the box 
denoted median and the filled circles denote outliers outside IQR ± 1.5 × IQR. * = P < 0.05 versus normal controls, ** = P < 0.05 versus OA. (b) Nuclear 
HAT activity was measured in synovial tissues that were obtained from normal controls (n = 3), OA (n = 5) and RA patients (n = 5). There was no sig-
nificant difference between normal controls, OA and RA synovial tissues.Kawabata et al. Arthritis Research & Therapy 2010, 12:R133
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resulted partly from the difference in the number of sam-
ples.
In chronic inflammation diseases, such as RA, TNFα is
a master cytokine that governs the disease process by
inducing a variety of inflammatory mediators through
activation of the transcription factor, NF-κB, and the
MAP kinase cascade. We examined the relationship
between nuclear HDAC activity and cytoplasmic TNFα
in synovial tissue (Figure 2). They were significantly cor-
related in OA synovial tissue, whereas they did not reach
statistically significant correlation in RA synovial tissues
(r = 0.517, P = 0.0852). These data imply a limitation of
the current study that nuclear HDAC activity and cyto-
plasmic TNFa levels in synovial tissues from RA patients
can be affected by medical treatments with DMARDs or
corticosteroid.
The previous study reported that TNFα modestly acti-
vated HDAC activity in airway smooth muscle cells [34].
Our in vitro study indicated that stimulation by TNFα
up-regulated HDAC activity in RASFs, suggesting the
downstream role of HDAC in exacerbation of the inflam-
mation, and that the inhibition of HDAC activity results
in the suppression of arthritis. Therefore, blockage of
TNF by biologic agents might result in the inhibition of
HDAC activation in synovial tissue.
On the other hand, anti-inflammatory effects shown by
inhibition of HDAC activity [15,19] might be associated
with the inhibition of the TNFα-induced NF-κB pathway.
In non-small cell lung cancer (NSCLC), the HDAC inhib-
itor superoylanilide hydroxamic acid (SAHA) displayed
antitumor efficacy by delayed IκB-α phosphorylation
[35]. Butyrate, a classical HDAC inhibitor, inhibited NF-
κB DNA binding within 30 minutes of TNFα stimulation,
consistent with the inhibition of NF-κB nuclear translo-
cation in colonocytes [36]. The influence of HDAC inhib-
itors on transcriptional co-factors or/and co-activators
after DNA binding of NF-κB still requires further investi-
gation in RA.
Figure 2 Correlation between the amount of cytoplasmic TNFα and nuclear HDAC activity in synovial tissues. Both cytoplasimc TNFα and nu-
clear HDAC activity were measured in synovial tissues that were obtained from osteoarthritis (n = 12), and rheumatoid arthritis (n = 12) patients. The 
cytoplasmic fraction was obtained during the isolation of the nuclear fraction, and analyzed by ELISA.Kawabata et al. Arthritis Research & Therapy 2010, 12:R133
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Figure 3 HDAC1-8 mRNA expression and correlation between TNFα mRNA and HDAC1 mRNA expressions in synovial tissues. Total RNA was 
extracted from total synovial tissues that were obtained from normal controls (n = 3), osteoarthritis (OA, n = 8) and rheumatoid arthritis (RA, n = 9) 
patients. (a) HDAC1-8 mRNA expression was analyzed by quantitative real-time PCR analysis as described in Materials and Methods. * = P < 0.05 versus 
OA, ** = P < 0.05 versus normal controls. (b) Correlation between TNFα mRNA expression and HDAC1 mRNA in RA synovial tissues (n = 10).Kawabata et al. Arthritis Research & Therapy 2010, 12:R133
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Next, we attempted to investigate HDAC specificity in
RA inflammation. In RA synovial tissues, we demon-
strated that HDAC1 was specifically up-regulated in
mRNA expression and protein levels. Western blot analy-
sis of class I HDACs in synovial tissues showed that the
expression of HDAC1 protein was significantly increased
in RA lesions, compared with OA lesions. In RASFs, only
HDAC1 mRNA and HDAC1 protein expression among
class I HDACs increased through the time courses after
TNFα stimulation, suggesting that HDAC1 overexpres-
sion might be associated with the enhanced inflamma-
tory reaction. A previous report showed the effects of
therapeutic administration of the HDAC inhibitor, SAHA
and MS-275 on disease progression and joint destruction
in collagen-induced arthritis in rat and mouse models
[22]. Although SAHA exhibited moderate prophylactic
efficacy, but could not inhibit the onset of arthritis, MS-
275 displayed dramatic anti-rheumatic activities. In pro-
Figure 4 Results of Western blot analysis for nuclear class I HDACs protein expressions in synovial tissues. (a) Class I HDACs (HDAC1, 2, 3, 8) 
protein expressions in synovial tissues that were obtained from osteoarthritis (OA, n = 3) and rheumatoid arthritis (RA, n = 3) synovial tissues. Lamin A, 
nuclear membrane protein, served as loading control. (b) Densitometric analysis class I HDACs protein in OA and RA synovial tissue was The data were 
plotted as means ± SE. * = P < 0.05 versus OA.Kawabata et al. Arthritis Research & Therapy 2010, 12:R133
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Figure 5 Nuclear HDAC activity, class I HDACs mRNA and protein expressions in RASFs after TNFα treatment. RASFs (n = 3) were treated with 
TNFα (10 ng/ml) and total nuclear protein was extracted at the indicated time points. (a) Nuclear HDAC activity was elevated significantly at 6 h. The 
data were plotted as means ± SE. * = P < 0.001 versus time 0 h, 24 h. (b) The expression of HDAC1 in RASFs was increased after TNFα treatment, while 
the expressions of other class I HDACs were not elevated. The increase of mRNA in HDAC1 at 24 h was significantly greater than that in other class I 
HDACs. For real-time PCR analysis, levels of mRNA were normalized against  actin expression and compared with 0 h. * = P < 0.05 versus HDAC2, 3, 
8. (c) Quantitative results of Western blot analysis of nuclear class I HDACs protein expression in RASFs. The band intensity of class I HDACs was mea-
sured by Image J software. For analysis, levels of protein expression were normalized by lamin A and compared with 0 h. * = P < 0.05 versus HDAC3 
and HDAC8 at 48 h.
 bKawabata et al. Arthritis Research & Therapy 2010, 12:R133
http://arthritis-research.com/content/12/4/R133
Page 11 of 13
phylactic intervention, high doses of MS-275 prevented
bone erosion, and displayed dramatic anti-rheumatic
activities. The authors concluded that the superior anti-
inflammatory effects of MS-275 might be due to its spec-
ificity towards class I HDACs, especially HDAC1.
The disruption of both HDAC1 alleles results in embry-
onic lethality, as a result of severe proliferation defects
and retardation in development [37]. Published data indi-
cate that HDAC1 knockdown by siRNA induces a mitotic
defect, cell growth inhibition, and an increased percent-
age of apoptotic cells in human tumor cells [38]. These
findings indicate that HDAC1 has important roles in
development and proliferative disease, which may include
tumor-like proliferative inflammatory disease, such as
RA. HDAC1 target genes include Bax, cytokeratin 18,
p21WAF1/Cip1, p27KIP1, p16INK4a  and p53 [18,37,39-41].
Especially, several studies suggest that the tumor sup-
pressor gene p53 is a key regulator in rheumatoid inflam-
mation. p53 mutations in RA synovial tissue and RASF
have been reported, although there is some variability in
the number of mutations identified [42,43]. Loss of p53
function in RASF and in collagen antibody-induced mice
enhances proliferation, cartilage invasion and anchorage-
independent growth while suppressing apoptosis, thereby
recapitulating the rheumatoid phenotype [38,44]. It is
known that HDAC1 deacetylates p53 in vitro and in vivo,
and down-regulates p53 transcriptional activity [45,46].
Effective degradation of p53 is mediated by the ubiquitin
ligase Mdm2, as well as in RA [47], and Mdm2 can pro-
mote p53 deacetylation by recruiting a complex contain-
ing HDAC1 [48]. Most recently, Horiuchi et al. also
showed HDAC1 is overexpressed in RASF compared to
OA synovial fibroblasts [41]. Knockdown of HDAC1 and
HDAC2 by siRNA resulted in increased expression of
p16, p21, and p53, and decreased cell counts and cell pro-
liferation, and increased apoptosis in RASF. These data
cumulatively support the idea that HDAC1 might be
involved in RA pathogenesis by regulating the cell cycle
of synovial tissue, and might contribute synovial inflam-
mation.
Conclusions
The relationship between histone acetylation and RA
pathogenesis has not been elucidated. Our results indi-
cate that higher HDAC activity might be linked with
higher amounts of cytoplasmic TNFα in RA synovial tis-
sues. Among HDACs, increased activity and expression
of nuclear HDAC1 in synovial cells might play a role in
RA inflammation.
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